Nasdaq
$1.48▲ 0.68%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.4MShares out 3.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
21- 1d agoPre-market26.10.23 13:15filedEFFECTOther#●●●#●●●
Pulmatrix, Inc.
The registration statement filed by Pulmatrix, Inc. was declared effective by the SEC on October 22, 2026. This filing confirms that the company is officially authorized to proceed with the issuance of new shares for capital raising purposes.…more
$1.48+0.68%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoPre-market26.10.22 19:05425Other
Pulmatrix, Inc.
Pulmatrix and Eos SENOLYTIX are set to complete their merger following a special meeting of stockholders scheduled for October 26, 2026. Upon completion, the combined company expects to trade on Nasdaq under the ticker symbol 'MTXL', while Eos has released new preclinical data for its lead geropeptide candidate, PTC-2105.…more
$1.48+0.68%vs prev closeView filingShare - 10.13Pre-market26.10.13 19:17425Other
Pulmatrix, Inc.
Pulmatrix and Eos SENOLYTIX are proceeding with a proposed merger, with a special stockholder meeting scheduled for October 26, 2026, to vote on the transaction. Upon completion, the combined company is expected to trade on Nasdaq under the new ticker symbol 'MTXL'.…more
$1.48+0.68%vs prev closeView filingShare
20 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.22 21:09#●●●#●●●
Eos SENOLYTIX Presents New Preclinical Data for PTC-2105 at Mitochondrial Congress…more
Eos SENOLYTIX showcased new preclinical survival and healthspan data for its lead candidate, PTC-2105, at the 17th World Congress on Targeting Mitochondria. While the presentation highlights progress in mitochondrial-targeted medicine, the candidate remains in the early stages of development.…more
$1.48+0.68%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 2d agoAfter-hours26.10.22 05:00
●●●●●●●● ●●●●● ●●●●●●
Pulmatrix has received a notice of allowance for a U.S. patent covering its dry powder dihydroergotamine formulations for migraine treatment. This patent strengthens the company's intellectual property protection for its therapeutic candidate.…more
$1.48+0.68%vs prev closeShareBenzinga - 9.22Pre-market26.09.22 21:33
●●●●●●●● ●●●●● ●●●●●●
Eos SENOLYTIX will deliver a keynote address at the 17th World Congress on Targeting Mitochondria in October. The company also announced that it expects to finalize its merger with Pulmatrix during the fourth quarter.…more
$1.48+0.68%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report